QLT Inc. - Product Pipeline Review - 2012

Global Markets Direct, May 2012, Pages: 65

QLT Inc. – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “QLT Inc. - Product Pipeline Review - 2012” provides data on the QLT Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, QLT Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from QLT Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- QLT Inc. - Brief QLT Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of QLT Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of QLT Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the QLT Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate QLT Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of QLT Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the QLT Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with QLT Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of QLT Inc. and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of QLT Inc.; QLT Inc. - Key Therapeutics; QLT Inc. - Pipeline Overview and Promising Molecules; QLT Inc. - News; QLT Inc. - Latest Updates; QLT Inc. - Pipeline; QLT Inc. - Discontinued/Dormant Projects

List of Tables
List of Figures
QLT Inc. Snapshot
QLT Inc. Overview
Key Information
Key Facts
QLT Inc. – Research and Development Overview
Key Therapeutic Areas
QLT Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
QLT Inc. – Pipeline Products Glance
QLT Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
QLT Inc. – Drug Profiles
Latanoprost Punctal Plug Delivery System
Product Description
Mechanism of Action
R&D Progress
Lemuteporfin
Product Description
Mechanism of Action
R&D Progress
QLT091001
Product Description
Mechanism of Action
R&D Progress
Visudyne + Lucentis + Dexamethasone
Product Description
Mechanism of Action
R&D Progress
QLT Inc. – Pipeline Analysis
QLT Inc. – Pipeline Products by Therapeutic Class
QLT Inc. – Pipeline Products By Target
QLT Inc. – Pipeline Products by Route of Administration
QLT Inc. – Pipeline Products By Mechanism of Action
QLT Inc. – Recent Pipeline Updates
QLT Inc. - Dormant Projects
QLT Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
QLT091568
Tariquidar
Tariquidar + Paclitaxel + Carboplatin
Tariquidar + Vinorelbine
QLT Inc. – Company Statement
QLT Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
QLT Inc., Recent Developments
QLT Inc.- Press Release
Apr 02, 2012: QLT To Present Data From Phase Ib Trial Of QLT091001 At ARVO
Mar 19, 2012: QLT Receives Orphan Drug Designation For Visudyne For Treatment of Central Serous Chorioretinopathy
Mar 01, 2012: QLT Announces Positive Preliminary Results From Phase Ib Trial Of QLT091001 In Subjects With Retinitis Pigmentosa
Dec 15, 2009: QLT Inc. Initiates Phase Ib Trial Study Of QLT091001 For The Treatment Of Leber Congenital Amaurosis (LCA)
Jul 28, 2009: Qlt Announces Interim Data From A Phase II Clinical Trial And A Device Study For A Punctal Plug Drug Delivery System
Mar 12, 2009: QLT Announces Completion Of Phase Ia Safety Trial Of Its Synthetic Retinoid Product QLT091001
Financial Deals Landscape
QLT Inc., Deals Summary
QLT Inc., Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
QLT Acquires OT-730 From Othera Pharma
QLT Acquires US Rights Of Visudyne From Novartis
QLT Acquires Full Rights To Aczone From Astellas
Partnerships
QLT Ophthalmics Enters Into Co-Promotion Agreement With Quantel Medical And Quantel USA
QLT Signs Agreement With Wilmer Eye Institute
Array BioPharma Enters Into Co-Development Agreement With QLT
Licensing Agreements
QLT Enters Into Licensing Agreement With Reckitt Benckiser
QLT Enters Into Licensing Agreement With Retinagenix
Asset Transactions
Valocor Therapeutics Acquires Rights To Novel Dermatology Programs From QLT
QLT Completes Sale Of Aczone To Allergan
QLT Completes Sale Of Its Generic Dermatology And Manufacturing Business To Tolmar
BioDelivery Sciences International Acquires BEMA Drug Delivery Technology From QLT
Acquisition
Tolmar Holding Acquires QLT USA From QLT
QLT Acquires ForSight Newco II
QLT Acquires Atrix Labs
QLT Acquires Kinetek Pharma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
QLT Inc., Key Information
QLT Inc., Key Facts
QLT Inc. – Pipeline by Indication, 2012
QLT Inc. – Pipeline by Stage of Development, 2012
QLT Inc. – Monotherapy Products in Pipeline, 2012
QLT Inc. – Combination Treatment Modalities in Pipeline, 2012
QLT Inc. – Phase II, 2012
QLT Inc. – Phase I, 2012
QLT Inc. – Pipeline By Therapeutic Class, 2012
QLT Inc. - Pipeline By Target, 2012
QLT Inc. – Pipeline By Route of Administration, 2012
QLT Inc. – Pipeline Products By Mechanism of Action, 2012
QLT Inc. – Recent Pipeline Updates, 2012
QLT Inc. - Dormant Developmental Projects,2012
QLT Inc. - Discontinued Pipeline Products, 2012
QLT Inc., Subsidiaries
QLT Inc., Deals Summary
QLT Acquires OT-730 From Othera Pharma
QLT Acquires US Rights Of Visudyne From Novartis
QLT Acquires Full Rights To Aczone From Astellas
QLT Ophthalmics Enters Into Co-Promotion Agreement With Quantel Medical And Quantel USA
QLT Signs Agreement With Wilmer Eye Institute
Array BioPharma Enters Into Co-Development Agreement With QLT
QLT Enters Into Licensing Agreement With Reckitt Benckiser
QLT Enters Into Licensing Agreement With Retinagenix
Valocor Therapeutics Acquires Rights To Novel Dermatology Programs From QLT
QLT Completes Sale Of Aczone To Allergan
QLT Completes Sale Of Its Generic Dermatology And Manufacturing Business To Tolmar
BioDelivery Sciences International Acquires BEMA Drug Delivery Technology From QLT
Tolmar Holding Acquires QLT USA From QLT
QLT Acquires ForSight Newco II
QLT Acquires Atrix Labs
QLT Acquires Kinetek Pharma

List of Figures
QLT Inc. – Pipeline by Indication, 2012
QLT Inc. – Pipeline by Stage of Development, 2012
QLT Inc. – Monotherapy Products in Pipeline, 2012
QLT Inc. – Combination Treatment Modalities in Pipeline, 2012
QLT Inc. – Pipeline By Therapeutic Class, 2012
QLT Inc. - Pipeline By Target, 2012
QLT Inc. – Pipeline By Route of Administration, 2012
QLT Inc. - Pipeline Products By Mechanism of Action, 2012

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• eBay - Strong Execution
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Scientific Games Corporation - Company Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Amazon - Point of Realization in 2013?
• Ixia - Company Analysis
• SunGard - Profile - US
• Insight into Samsung Electronics' Notebook PC Business Model
• US - Accenture - Company Profile